SOCIETY FOR PEDIATRIC PATHOLOGY 2020 SPRING MEETING

February 28 - March 1, 2020
SPP Spring 2020 Meeting
Doubletree by Hilton Hotel Los Angeles Downtown
SPP Board of Directors
President       Charles Timmons
Past-President     Sara Vargas
President-Elect      Gino Somers
Treasurer      Linda Ernst
Secretary     Fusun Gundogan
Board of Directors
Miguel Reyes-Mugica
Shamlal Mangray
Rebecca Baergen
Megan Dishop
Laura Finn
Jim Wright
Sanda Alexandrescu
Raffaella Morotti
Vivekanand Singh
Nina Tatevian

Committee Chairs
Education     Sanda Alexandrescu
CME Course Advisor    Lili Miles
Fellowship     Raja Rabah
Finance     Sarah Johnson-Welch
Informatics & Communications   Jason Jarzembowski
Membership     Erin Rudzinski
Perinatal     Debra Heller
Practice     Dolores Lopez-Terrada
Publications     Monique de Paepe
Research & Awards    Jefferson Terry

2020 Spring Meeting Program Chairs
Education     Sanda Alexandrescu
CME Course Advisor    Lili Miles
Abstracts     Benjamin Wilkins
Workshops     Jessica Davis
Symposium     Alison Huppmann
MEETING NEEDS ASSESSMENT
The practice of pediatric pathology requires up-to-date knowledge of the diseases affecting children, including their scientific basis, clinical spectrum, pathologic classification, and current research activities. The Society for Pediatric Pathology Annual Meeting is intended as an ongoing resource to meet the educational needs of pediatric pathologists, general pathologists whose practice includes pediatric pathology, pediatric pathology fellows, and pathology residents.

MEETING OBJECTIVES
Upon completion of this meeting, learners should be able to:

- Acknowledge recent advancements in research and practice related to the biology, characterization and/or diagnosis of pediatric disease.
- Identify areas with recent significant advancement in the practice of pediatric pathology.
- Implement diagnostic and consultative management updates in pediatric pathology into practice.
- Summarize clinicopathologic differential diagnoses and pathologic processes of perinatal and pediatric disorders and their complications, as well as their treatments and possible outcomes.

Disclosure of Conflicts of Interest
Disclosure Policy
The Society for Pediatric Pathology requires faculty and members of the planning committee to disclose whether or not they have any relevant commercial relationships or if they will be discussing unlabeled and/or investigational uses of any products, pharmaceuticals, or medical devices. This must be made known in advance to the audience in accordance with the ACCME Standards of Commercial Support guidelines.

Program Committee Disclosures
Every person who is involved in the planning of this CME program has been asked to provide information regarding any financial relationships with a commercial interest as defined by the ACCME. The following program committee members have indicated that they have financial relationships to disclose. They have agreed to disclose this to participants. Any other committee member disclosures not yet received will be included in a program addendum.

<table>
<thead>
<tr>
<th>First</th>
<th>Last</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin</td>
<td>Wilkins</td>
<td>Genmab Inc, Employee (spouse)</td>
</tr>
</tbody>
</table>

2020 Spring Meeting Faculty Disclosures
All faculty members are required to disclose any financial relationships with a commercial interest as defined by the ACCME. The following faculty indicated that they have financial relationships to disclose. They have agreed to disclose this to participants. Any other faculty disclosures not yet received will be included in a program addendum.
<table>
<thead>
<tr>
<th>First</th>
<th>Last</th>
<th>Financial Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark</td>
<td>Gebhardt</td>
<td>Clinical Orthopaedics and Related Research - journal. Salary support as a Senior Editor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Up-to-Date - reviewer. I receive royalties for reviewing content on MSK tumors</td>
</tr>
<tr>
<td>Kathleen</td>
<td>Nicol</td>
<td>DeepLens, consultant</td>
</tr>
<tr>
<td>Alanna</td>
<td>Church</td>
<td>• 1. Jackson Laboratories, Consultant and Speaker</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 2. Bayer Oncology, Consultant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 3. Bio-Rad Laboratories, Speaker</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 4. Samba Scientific, Consultant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 5. AlphaSights, Consultant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 6. Perceptive Advisors, Consultant</td>
</tr>
</tbody>
</table>

**Unlabeled/Investigation Uses of Products or Devices**

There will be no use of unlabeled/investigation of products or devices.

**CONTINUING MEDICAL EDUCATION ACCREDITATION**

**Accreditation Statement**

The Society for Pediatric Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**AMA Credit Designation Statement – SPP Spring Meeting**

The Society for Pediatric Pathology designates this live activity for a maximum of 14.5 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**International Physicians**

The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for *AMA PRA Category 1 Credit(s)™*.

**Health Professionals**

Health Professional participants (including residents and fellows-in-training) may claim hours to receive a Certificate of Participation for an activity designated for *AMA PRA Category 1 Credit(s)™*.

**CME Credits**

Certificates of continuing medical education *AMA PRA Category 1 Credits™* will be issued through the Society for Pediatric Pathology. CME credits will only be awarded after completion of an online evaluation form.

*AMA PRA Category 1 Credits™* offered for SPP Spring 2020:

<table>
<thead>
<tr>
<th>Activity</th>
<th>Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Sessions</td>
<td>6.5</td>
</tr>
<tr>
<td>Symposium</td>
<td>3.0</td>
</tr>
<tr>
<td>Farber-Landing Lecture</td>
<td>1.0</td>
</tr>
<tr>
<td>Workshops</td>
<td>2.0 credits each</td>
</tr>
</tbody>
</table>
An evaluation must be completed prior to claiming CME credit for the various offerings. The evaluation forms, CME claim forms and SAMs post-tests can be accessed through the SPP website: [www.spponline.org](http://www.spponline.org)

You have 90 days from the end of the meeting to claim credit.

## SELF-ASSESSMENT MODULE CREDITS

The SPP is accredited by the American Board of Pathology to offer Self-Assessment Module (SAMs) credits for the purpose of meeting the American Board of Pathology requirements for the Continuing Certification Program. Registrants must take and pass the post-test in order to claim SAMs credit(s). SAMs credits are being offered for the elective workshops and symposium ONLY. (Maximum of 7 SAMs credits available)

## SOCIETY FOR PEDIATRIC PATHOLOGY

**SPRING MEETING 2020**

**PROGRAM SUMMARY**

February 28 – March 1, 2020

120 S Los Angeles Street

Los Angeles, CA 90012, USA

### Friday, February 28, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m. – 6:00 p.m.</td>
<td>Registration Open</td>
<td>Ballroom Foyer</td>
</tr>
<tr>
<td>8:00 a.m. – 10:00 a.m.</td>
<td>Executive Committee (closed)</td>
<td>California AB</td>
</tr>
<tr>
<td>9:00 a.m. – 12:00 noon</td>
<td>Education Committee Meeting</td>
<td>California CD</td>
</tr>
<tr>
<td>10:00 a.m. – 11:30 a.m.</td>
<td>Finance Committee (open)</td>
<td>California AB</td>
</tr>
<tr>
<td>11:30 a.m. – 1:00 p.m.</td>
<td>PDP Editorial Board Meeting with Lunch (by invitation)</td>
<td>San Diego</td>
</tr>
<tr>
<td>12:00 noon – 5:00 p.m.</td>
<td>Exhibitors Set-Up</td>
<td>Golden Prefunction</td>
</tr>
<tr>
<td>1:00 p.m. – 5:00 p.m.</td>
<td>General Session Set-up</td>
<td>Golden Ballroom</td>
</tr>
<tr>
<td>1:00 p.m. – 2:00 p.m.</td>
<td>Membership Committee (open)</td>
<td>California AB</td>
</tr>
<tr>
<td>1:00 p.m. – 2:00 p.m.</td>
<td>Practice Committee (open)</td>
<td>Los Angeles</td>
</tr>
<tr>
<td>1:00 p.m. – 2:00 p.m.</td>
<td>Informatics and Communications Committee Meeting (open)</td>
<td>California CD</td>
</tr>
<tr>
<td>1:00 p.m. – 2:30 p.m.</td>
<td>Research and Awards Committee (closed)</td>
<td>Los Angeles</td>
</tr>
<tr>
<td>2:00 p.m. – 3:00 p.m.</td>
<td>Fellowship Committee (open)</td>
<td>Sacramento</td>
</tr>
<tr>
<td>2:00 p.m. – 3:00 p.m.</td>
<td>Perinatal Committee (open)</td>
<td>California CD</td>
</tr>
<tr>
<td>2:00 p.m. – 3:30 p.m.</td>
<td>Publications Committee (open)</td>
<td>San Diego</td>
</tr>
<tr>
<td>2:30 p.m. – 4:00 p.m.</td>
<td>Slide Survey Subcommittee (closed)</td>
<td>California CD</td>
</tr>
<tr>
<td>4:00 p.m. – 6:00 p.m.</td>
<td>Board of Directors Meeting (by invitation)</td>
<td>California AB</td>
</tr>
</tbody>
</table>

### Saturday, February 29, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m. – 6:00 p.m.</td>
<td>Registration Open</td>
<td>Golden Prefunction</td>
</tr>
<tr>
<td>7:00 a.m. – 6:00 p.m.</td>
<td>Poster Hall Open</td>
<td>Thousand Cranes</td>
</tr>
<tr>
<td>7:00 a.m. – 6:00 p.m.</td>
<td>Exhibit Hall Open</td>
<td>Golden Prefunction</td>
</tr>
<tr>
<td>7:00 a.m. – 8:00 a.m.</td>
<td>Continental Breakfast for All Attendees</td>
<td>Golden Prefunction</td>
</tr>
<tr>
<td>7:00 a.m. – 8:00 a.m.</td>
<td>New Member/Trainee Breakfast</td>
<td>San Diego</td>
</tr>
<tr>
<td>8:00 a.m. – 8:05 a.m.</td>
<td>Welcome</td>
<td>Golden Ballroom</td>
</tr>
<tr>
<td>8:05 a.m. – 10:20 a.m.</td>
<td>Platform Presentation I</td>
<td>Golden Ballroom</td>
</tr>
<tr>
<td>10:20 a.m. – 10:50 a.m.</td>
<td>Refreshment Break &amp; Poster Viewing</td>
<td>Thousand Cranes</td>
</tr>
<tr>
<td>10:50 a.m. – 11:50 a.m.</td>
<td>Platform Presentation II</td>
<td>Golden Ballroom</td>
</tr>
<tr>
<td>12:15 p.m. – 1:15 p.m.</td>
<td>Business Meeting</td>
<td>Golden Ballroom</td>
</tr>
</tbody>
</table>

*(All SPP members welcome)*

*Lunch provided for free in Golden Ballroom*
1:30 p.m. – 5:00 p.m.  
**Symposium: Pediatric Bone Lesions; Practical Approach**  
*Golden Ballroom*

- 1:30 – 1:35 - Introduction and Welcome - Alyaa Al-Ibraheemi, MD
- 1:35 – 2:20 - Radiologic-Pathologic Correlation, What Pathologists Need to Know - Miriam A Bredella, MD
- 2:20 – 2:40 - General Approach to Bone Pathology - Gunnlaug Petur Nielsen, MD
- 2:40 – 2:55 - Challenges Encountered at Interpreting Core Biopsies and Intraoperative Frozen Sections - Gunnlaug Petur Nielsen, MD

2:55 p.m. – 3:25 p.m.  
**Afternoon Break**  
*Ballroom Foyer*

- 3:25 – 4:00 - Benign Bone Lesions and Reactive Conditions Mimicking Neoplasia, Practical Approach - Alyaa Al-Ibraheemi, MD
- 4:00 – 4:40 - What Surgeons Want to Know from Pathology Reports and Frozen Sections Diagnosis - Mark Gebhardt, MD
- 4:40 – 5:00 - 20 minute Q&A/Panel Discussion - all speakers

5:00 p.m. – 5:30 p.m.  
**Perinatal Business Meeting – All Members Welcome**  
*Golden Ballroom*

6:00 p.m. – 6:45 p.m.  
**Poster Blitz**  
*Golden Ballroom*

6:45 p.m. – 7:00 p.m.  
**President’s Inaugural Address**  
(No CME credit)  
*Golden Ballroom*

7:00 p.m. – 8:00 p.m.  
**Cocktail Reception / Music / Speak with Presenters**  
*Golden Ballroom*

---

**Sunday March 1, 2020**

7:00 a.m. – 2:00 p.m.  
**Registration Open**  
*Golden Prefunction*

7:00 a.m. – 8:00 a.m.  
Continental Breakfast for All Attendees  
*Ballroom Foyer*

7:00 a.m. – 12:00 noon  
**Poster Viewing**  
*Thousand Cranes*

7:00 a.m. – 12:00 noon  
**Exhibits Open**  
*Thousand Cranes*

8:00 a.m. – 9:30 a.m.  
Platform III – *Neuropathology and Immuno-oncology*  
*Golden Ballroom*

9:30 a.m. – 10:30 a.m.  
Platform IV – *GI/Pulmonary*  
*Golden Ballroom*

10:30 a.m. – 11:00 a.m.  
Refreshment Break & Poster Viewing  
*Thousand Cranes*

11:00 a.m. – 12:00 noon  
**Farber-Landing Lecture:**  
Rhabdomyosarcoma: From Obscurity to Clarity in Diagnosis, but with Ongoing Challenges in Management  
David Parham, MD  
*Golden Ballroom*

12:00 noon – 12:20 p.m.  
**Awards Presentation**  
*Golden Ballroom*

12:30 p.m.  
Exhibits & Poster Dismantle  
*Thousand Cranes*

12:20 p.m. – 1:30 p.m.  
Lunch on your own  
*Thousand Cranes*

1:30 p.m. – 3:30 p.m.  
**Workshop Session I:**  
(Ticket is required)

- **A - Year 1/3:** Discovering Cancer Predisposition in Children  
  California
- **B - Year 2/3:** What Can the Placenta Tell Us?  
  Sacramento
- **C - Year 3/3:** What every Pediatric Pathologist Needs to Know:  
  WHO Classification of Tumors of the Central Nervous System  
  Pediatric Tumors  
  Los Angeles

3:30 p.m. – 4:00 p.m.  
**Workshop Afternoon Break**  
*Golden Prefunction*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 p.m.</td>
<td><strong>Workshop Session II</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Ticket is required)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>D - Year 1/3:</strong> Hirschsprung Disease: Diagnostic, Intra-operative, and Post-operative</td>
<td>California</td>
</tr>
<tr>
<td></td>
<td><strong>E - Year 2/3:</strong> Role of Bias in Pediatric Pathology: Preventing Errors and Enhancing Patient Safety One Child at a Time. (American Board of Pathology approved Patient Safety Course)</td>
<td>Sacramento</td>
</tr>
<tr>
<td></td>
<td><strong>F - Year 3/3:</strong> Bone dysplasias: A Systematic Diagnostic Approach.</td>
<td>Los Angeles</td>
</tr>
</tbody>
</table>
Platform Session 1 – Neoplasia  
Room: Golden Ballroom

Saturday, February 29, 2020

8:05 a.m. – 10:20 a.m.

Platform Session 1 – Neoplasia
Moderators: Juan Putra, MD & Robin LeGallo, MD

1 Two Distinct Patterns of MYCN Protein Expression in Stage 4S Neuroblastomas: A Report from the COG Neuroblastoma Study
   A Kawano¹, F Hazard², A Naranjo³, B LaBarre⁴, W London⁴, M Hogarty⁵, S Cohn⁶, J Maris⁷, J Park⁸, J Gastier-Foster⁴, N Ikegaki⁹, H Shimada²; ¹Chiba University of Graduate School of Medicine, Chiba; ²Stanford University, Stanford, California; ³University of Florida, Gainsville, Florida; ⁴Boston Children's Hospital, Boston, Massachusetts; ⁵The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; ⁶University of Chicago Medicine, Chicago, Illinois; ⁷Seattle Children's Hospital, Seattle, Washington; ⁸Baylor College of Medicine, Houston, Texas; ⁹University of Illinois at Chicago, Chicago, Illinois

2 Pediatric Granular Cell Tumors: Clinicopathologic and Molecular Analysis of Six Cases Including Multicentric, Atypical, Malignant, and Non-Neural Tumors
   E Nohr¹, J Slack¹, E Chan¹, K Kurek¹, M Brundler¹; ¹Cumming School of Medicine, Calgary

3 Utility of p53, ATRX, and H3K27Me3 Immunohistochemical Staining in Distinguishing Osteosarcoma from Histologic Mimics
   G Rose¹, F Bu¹, S Koo¹; ¹Nationwide Children's Hospital, Columbus, Ohio

4 USP6 RNA Expression by Targeted RNA NGS to Rescue Missing Fusions
   Y Lo¹, S Duraisamy¹, S Cano¹, L Grimmett¹, J Plunkitt¹, Y Mei¹, H Tsai¹, T Restrepo¹, M Harris¹, A Church¹; ¹Boston Children's Hospital, Boston, Massachusetts

5 DNA Methylation and Copy Number Profiling in Pediatric BCOR-ITD
   C Salgado¹, R Alaggio¹, F Locatelli¹, F Camassei¹, G Bisogno³, E Miele²; ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania; ²Ospedale Bambino Gesù, Rome; ³University of Padova, Padova

6 The Prognostic Significance of Anaplasia in Childhood Rhabdomyosarcoma: A Report from the Children’s Oncology Group
   A Shenoy¹, E Alvarez¹, Y Chi¹, M Li¹, J Shern¹, J Khan¹, S Hiniker¹, C Granberg⁶, D Hawkins¹, D Parham¹, L Teot¹, E Rudzinski¹; ¹University of Florida/Shands Childrens Hospital, Gainesville, Florida; ²UC Davis Health, Sacramento, California; ³University of Florida College of Medicine, Gainesville, Florida; ⁴Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; ⁵Stanford University, Palo Alto, California; ⁶Mayo Clinic, Rochester, Minnesota; ⁷Seattle Children's Hospital, Seattle, Washington; ⁸Children's Hospital Los Angeles Pathology and Laboratory Medicine, Los Angeles, California; ⁹Boston Children's Hospital, Boston, Massachusetts
9:35 – 9:50 a.m.  7  Prognostic Significance of Inflammatory Microenvironment in Post-transplant Lymphoproliferative Disorder as a Potential Method to Identify High Risk Patients
*A Drohysheva*, *G Pinkus*, *O Weinberg*; Boston Children’s Hospital, Boston, Massachusetts; 2Brigham And Women’s Hospital, Boston, Massachusetts

9:50 – 10:05 a.m.  8  Does the Use of a Next Generation Sequencing Assay Improve Diagnostic Accuracy in Pediatric Fibroblastic/Myofibroblastic Tumors?
*J Slack*, *E Nohr*, *M Brundler*, *K Kurek*; 1Cumming School of Medicine, Calgary

10:05 – 10:20 a.m.  9  Implementing Telepathology to Improve a Pediatric Fine Needle Aspiration Service: an Institutional Experience

10:50 – 11:50 a.m.

**Platform Session 2 – Perinatal**

**Moderators: Claudia Salgado, MD & Selene Koo, MD**

**Room: Golden Ballroom**

10:50 - 11:05 a.m.  10  Grading Fetal Vascular Malperfusion in the Placenta and Short Term Perinatal Outcome
*J Stanek*; 1Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

11:05 – 11:20 a.m.  11  Magnetic Resonance Imaging: Retrospective Analysis of in Vivo MRI and Placental Pathology
*C Bockoven*, *T Victor*, *J Meyer*, *B Petrovic*, *L Ernst*; 1NorthShore University HealthSystem, Evanston, Illinois

11:20 – 11:35 a.m.  12  Placental Chronic chorioamnionitis Is Associated with Offspring Asthma in Pregnancies with Maternal History of Asthma
*M He*, *H Mirzakhani*, *L Chen*, *A Litonjua*, *L Bacharier*, *S Weiss*, *M Nelson*; 1Washington University School of Medicine in St. Louis, St. Louis; 2Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts; 3Rochester University School of Medicine, Rochester, New York

11:35 – 11:50 a.m.  13  Kaiser Neonatal Early-Onset Sepsis Risk Score and Histologic Evidence of Infection in Antibiotic-Treated Group B Streptococcus-Positive Mothers
*M Gondim*, *J Hata*; 1Norton Children's Hospital/University of Louisville, Louisville, Kentucky

1:30 - 5:00 p.m. - Symposium

**Room: Golden Ballroom**

“Pediatric Bone Lesions; Practical Approach”

Organizers: Alyaa Al-Ibraheemi, MD, Boston Children’s Hospital, and Gunnlaugur Petur Nielsen, MD, Massachusetts General Hospital

The symposium on Pediatric Bone pathology will discuss commonly encountered primary bone lesions in children with focus on practical approach, correlation with radiologic findings. It will also discuss challenging encounters while evaluating frozen sections and needle biopsies, along with triaging bone biopsy.
The symposium will include a section on how to apply cost-effective ancillary studies and the usefulness of immunohistochemistry in working up bone lesions.

“Radiologic-Pathologic Correlation, What Pathologists Need To Know” – Miriam A Bredella, MD; Massachusetts General Hospital

At the end of this presentation, participants should be able to:
• Interpret specific imaging findings that indicate malignancy in pediatric bone tumors
• Identify imaging findings of benign pediatric bone lesions
• Diagnose non-neoplastic conditions that can mimic neoplasia

“General Approach to Bone Pathology” – Gunnlaugur Petur Nielsen, MD; Massachusetts General Hospital

At the end of this presentation, participants should be able to:
• Recite the radiographic features of common bone tumors
• Recognize the histologic features of more common bone tumors
• Describe how immunohistochemistry may help with diagnosing selected tumors

“Challenges encountered at interpreting core biopsies and intraoperative frozen sections” – Gunnlaugur Petur Nielsen, MD; Massachusetts General Hospital

At the end of this presentation, participants should be able to:
• Acknowledge the purpose of needle core frozen section diagnosis
• Identify the limitation of frozen section needle core biopsies
• Describe the application of frozen sections on resection specimens

“Benign Bone Lesions and Reactive Conditions Mimicking Neoplasia, Practical Approach” – Alyaa Al-Ibraheemi, MD; Boston Children’s Hospital

At the end of this presentation, participants should be able to:
• Comprehend commonly encountered pediatric bone lesions with focus on benign and non-neoplastic conditions mimicking neoplasia
• Grasp the key histologic features necessary for the differential diagnosis of pediatric bone lesions
• Acknowledge the importance of interdisciplinary approach when working up bone lesions

“What Surgeons Want to Know from Pathology Reports and Frozen Sections Diagnosis” – Mark Gebhardt, MD; Boston Children’s Hospital

At the end of this presentation, participants should be able to:
• Recite the main points of a bone tumor pathology report (e.g., diagnosis, grade, neoplasm type)
• Describe what the surgeon expects from an intra-operative frozen section (benign versus malignant, need for more tissue, special processing) and will see examples of difficult diagnoses and the approach to establishing the best diagnosis (second opinions, joint surgeon-pathologist review of histology)
• List what the surgeon needs to know following a tumor resection (e.g., margin, percent necrosis, frozen section data)
6:00 – 6:45 p.m.
Session - Poster Blitz
Moderator: Benjamin Wilkins, MD

Room: Thousand Cranes Ballroom

6:00:00 - 6:01:10 pm  24 Two Unexpected Cases of Pediatric “Kaposiform” Vascular Anomalies Involving the Pancreas
A Bernieh1, J Stanek1, C Merrow1, A Miethke1, K Ricci1, J Nathan1, M Abu-El-Haija2, A Gupta1; 1Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; 2Cincinnati Children's Hospital, Cincinnati, Ohio

6:01:10 - 6:02:20 pm  25 Gender-Discordant Monochorionic-Diamniotic Twins both with 45, X/46, X, idic (Y) Mosaicism and a Novel Gene Mutation
M Diamond1 (co-first author), A Inamdar1 (co-first author), W Shertz2; 1Saint Barnabas Medical Center, Livingston, New Jersey; 2Monmouth Medical Center, Long Branch, New Jersey

6:02:20 - 6:03:30 pm  26 PIK3R1 Gene: A Possible Culprit for Trans-Lineage Differentiation from Myeloid to Lymphoid Series
M Aldulescu1, K Yap1, S Gong1; 1Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

6:03:30 - 6:04:40 pm  27 Infantile Fibrosarcoma Presenting With Kasabach-Merritt Phenomenon, Involving The Thigh And Placenta: A Proposal Of Metastasis By Mesenchymal Migration
B Naumchik1, B Weigel2, M Murati3, E Rudzinski4, M Dolan1, S Flanagan5, M Luquette1; 1University of Minnesota, Department of Laboratory Medicine and Pathology, Minneapolis, Minnesota; 2University of Minnesota, Department of Pediatrics, Hematology-Oncology, Minneapolis, Minnesota; 3University of Minnesota, Department of Radiology, Minneapolis; 4Seattle Children's Hospital, Dept. of Laboratories, Seattle, Washington; 5University of Minnesota, Department of Radiology, Interventional Radiology, Minneapolis

6:04:40 - 6:05:50 pm  28 MALT Lymphoma in Gastrointestinal Tract: An Uncommon Form of Monomorphic Post-Transplant Lymphoproliferative Disorder with Both EBV-Positive and Negative Forms
L Barnea Slonim1, C Mehrhoff2, A Richardson2, S Gong2; 1Northwestern Memorial Hospital, Chicago, Illinois; 2Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois

6:05:50 - 6:07:00 pm  29 Follicular Thyroid Carcinoma: A Rare Second Malignancy in Children with Retinoblastoma
J Kurtz1, F Hazard1; 1Stanford University, Stanford, California

6:07:00 - 6:08:10 pm  30 Myogenin Expression in Benign Skeletal Muscle Tumors: A Potential Pitfall
L Berklite1, L Santoro2, V Donofrio3, A Stracuzzi4, J Ozolek5; 1University of Pittsburgh Medical Center Department of Pathology, Pittsburgh, Pennsylvania; 2Azienda Ospedaliera di Padova, Padova, Italy; 3Ospedale Pediatrico Pausilipon, Napoli, Italy; 4Ospedale Pediatrico Bambino Gesu, Roma, Italy; 5West Virginia University Department of Pathology, Morgantown, West Virginia
31 Aggressive Pediatric Adrenal Cortical Carcinoma With a Novel Translocation t(20;22) Fused MN1 and ZNF341
J Ly1, J Reid1, E Rubin2, A Nael3; 1UCI Medical Center, Orange, California; 2CHOC Children's Hospital, Orange, California; 3UCI Medical Center and CHOC Children's Hospital, Orange, California

32 Subcutaneous Inguinal Myxoid Liposarcoma: Rare Entity In A Rare Location
A Alhussain1, A Bernal1, Y Alhmada1; 1University Of Mississippi Medical Center, Jackson, Mississippi; 2Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

33 The Morphological Connection Between Ewing Sarcoma and Neuroblastoma Pediatric Tumors
L Curwick1, J Jarzembowski1, L Parsons1; 1Children’s Wisconsin, Department of Pathology, Milwaukee, Wisconsin

34 Cystic Fibrosis (CF) Mimics Biliary Atresia (BA): Histology of Liver and Extrahepatic Biliary Tree (EHB) in Three Cases With Kasai Portenterostomy (KHPE)
A Bernal1, E Yang2, J Picarsic1, K Bove1; 1Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; 2Peacehealth Sacred Heart Medical Center, Springfield, Oregon

35 Secretary Carcinoma in Children and Adolescents: A Case Series
C Simon1, R Rabah-Hammad1, J McHugh1, A Heider1; 1University of Michigan, Ann Arbor, Michigan

36 The Role of a Safety Skills Curriculum for the Anatomic Pathology Trainee
N Larsen1, S Joseph1, M Lurken1, C Magi-Galuzzi1, J Hackney1, I Eltoum1, V Duncan1; 1University of Alabama at Birmingham, Birmingham, Alabama

37 Gaucheroma - An Emerging Complication in Patients with Gaucher Disease with Long-Term Enzyme Replacement Therapy
M Warren1, S Yano2; 1Children’s Hospital Los Angeles, Los Angeles, California; 2Keck School of Medicine, University of Southern California, Los Angeles, California

38 A Malignant Mimicker: Features of Kikuchi-Fujimoto Disease in the Pediatric Population
K Chisholm1, K Tsuchiya1, V Paulson2; 1Seattle Children's Hospital, Seattle, Washington; 2University of Washington, Seattle, Washington

39 Monochorionic Triplet Pregnancies with Twin Reversed Arterial Perfusion (TRAP) and Acardiac Triplet: Case Series and Literature Review
A Mon1, K Thompson1; 1University of Hawaii Pathology Residency Program, Honolulu, Hawaii; 2John A. Burns School of Medicine Department of Pathology, Honolulu, Hawaii

40 Clinical Significance of CD31/CD68 Interpretation in Complex Heart Transplant Biopsies
J Pogoriler1, K Lin1, T Bhatti1, P Kreiger1, S Stamp1, C Carreon1; 1Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

41 Sloughing Esophagitis in the Pediatric Age Group: Clinicopathologic Characteristics of Twelve Cases
A Rubrecht1, D Saulino1, E Nasri1, A Esnakula1, D Gonzalo1, M Feely1, G Beasley1, A Shenoy1; 1University of Florida, Gainesville, Florida
Colon Metabolomic Changes in SIDS
J Terry1, R Dyer2, 1BC Children’s Hospital, Vancouver; 2BC Children’s Hospital Research Institute, Vancouver

Hydrops Fetalis in Hawaii: An Epidemiological Study
A Mon1, K Thompson2; 1University of Hawaii Pathology Residency Program, Honolulu, Hawaii; 2John A. Burns School of Medicine Department of Pathology, Honolulu, Hawaii

Curation of Clinically Actionable Variants in Pediatric Cancers Within the Clinical Genome Resource (ClinGen)
A Church1, A Roy2, S Rao3, D Ritter4, A Danos4, K Krysiak4, L Corson5, K Fisher3, H Williams6, M Hiemenz7, K Janeway8, J Ji9, M Harris1, C Kesserwan9, T Laetsch10, D Parsons2, R Schmidt11, K Sund11, W Lin12, M Griffith4, O Griffith4, S Kulkarni13, S Madhavan14, G Raca1; 1Boston Children’s Hospital, Boston, Massachusetts; 2Texas Children’s Hospital, Houston, Texas; 3Georgetown University Medical Center, Washington, District of Columbia; 4Washington University, St. Louis, Missouri; 5Dana Farber Cancer Institute, Boston, Massachusetts; 6Columbia University Medical Center, New York, New York; 7Children’s Hospital of Los Angeles, Los Angeles, California; 8Dana-Farber / Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts; 9Montefiore Medical Center, Bronx, Massachusetts; 10UT Southwestern Medical Center, Dallas, Texas; 11Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; 12Mayo Clinic, Jacksonville, Florida; 13Baylor College of Medicine, Houston, Texas; 14Georgetown University, Washington, District of Columbia

High-Grade Sarcoma With PTCH1 Mutation: Report of a Unique Case With Histologic Features of Sclerosing Epithelioid Fibrosarcoma
B Wilkins1; 1Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Gauging the Effectiveness of Pediatric Pathology Fellowship Training for Pediatric Dermatopathology Specimens: Interpreting the Preliminary Results for A National Survey
S Kelley1, T Enos2, T Vandergriff2, D Rakheja1; 1University of Texas Southwestern/Childrens Medical Center Dallas, Dallas, Texas; 2University of Texas Southwestern, Dallas, Texas

Tissue Transglutaminase and Deamidated Gliadin Peptidei In Tandem: A Comparison of Sensitivity and Specificity in A Pediatric Population
M Pacheco1, D Lee1, J Dickerson1; 1Seattle Children’s Hospital, Seattle, Washington

TLE1 and BCOR expression in Pediatric Angiomatoid Fibrous Histiocytoma: Diagnostic utility and pitfalls
J Byers1, H Yin1, H Ryning2, S Logan4, M He1, Z Yu1, D Wang4, S Mangray5, M Warren1, S Zhou1; 1Children’s Hospital Los Angeles, Los Angeles; 2Children’s Healthcare of Atlanta, Atlanta, Georgia; 3Washington University in Saint Louis, Saint Louis, Missouri; 4University of Oklahoma Health Sciences Center, Oklahoma, Oklahoma; 5Cincinnati Children’s Hospital, Cincinnati, Ohio; 6Rhode Island Hospital, Providence, Rhode Island

Birth Weight: Placental Weight Ratio in Autopsy of Term Stillbirth
P Skaria1, H Krigman1, L Dehner1, M He1; 1Washington University in Saint Louis, Saint Louis, Missouri

Using Image-guided Needle Core Biopsies to Obtain Molecular Genetics in Pediatric Lymphatic-Vascular Malformation J. C. Guerrero, P. Kreiger, and L. F. Surrey
The Children’s Hospital of Philadelphia, Philadelphia, PA, U.S.A.
J Guerrero1, P Kreiger1, L Surrey4; 1The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
51 Pediatric Renal Cell Carcinomas: A Single Institutional Study of 20 cases
M Narasimhamurthy¹, C Morrison², T Bhatti¹, P Russo¹, P Lal²; ¹The Children Hospital of Philadelphia, Philadelphia, Pennsylvania; ²Hospital of Pennsylvania, Philadelphia, Pennsylvania

52 Rhabdomyoblastic Differentiation in Wilms Tumor Portends Worse Prognosis
L Goetz¹, H Reinhardt², K Gvozdanj¹, J Fanburg-Smith¹; ¹Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania; ²Nationwide Children's Hospital, Columbus, Ohio; ³Loyola University Medical Center, Maywood, Illinois

53 Assessment of Histopathologic and Ultrastructural Features of Wilson Disease in Pediatric and Adult Patients
D Abuquteish¹, R Chami², O Adyiy³, I Siddiqui³; ¹Toronto General Hospital, Toronto; ²Hospital for Sick Children, Toronto; ³University of Minnesota Medical School, Minneapolis, Minnesota

54 Chondrosarcoma and Mesenchymal Chondrosarcoma: A Study Of 12 Pediatric Cases and Review of the Literature
R Felix¹, J Fouli², N Rahoui², J Reith³, A Alazraki⁴, E Demian², B Shehata²; ¹Children's Hospital of Michigan, Detroit, Michigan; ²CHM, Detroit, Michigan; ³Cleveland Clinic Foundation, Cleveland, Ohio; ⁴Emery University School of Medicine, Atlanta, Georgia

55 TERT Promoter Mutations in Hepatocellular Neoplasms-Not Otherwise Specified (HCN-NOS)
S Zhou¹, S Sarabia², D Lopez-Terrada²; ¹Children's Hospital Los Angeles, Los Angeles; ²Texas Children's Hospital, Houston, Texas

56 Fine Needle Aspiration (FNA) for Superficial Lymphadenopathy: A Retrospective Analysis of Accuracy and Pathologist Utilization of Ancillary Testing at a Large U.S. Pediatric Hospital
A Thaker¹, A Sengupta¹, H Luu¹, D Zwick¹; ¹UT Southwestern/Children's Health, Dallas, Texas

57 Pathologic Characterization of Pediatric Umbilical Lesions and Their Association with Postoperative Complications
J Prieto¹, H Thangarajah¹, S Tucker¹; ¹Rady Children's Hospital, San Diego, California

58 Diagnosis of Hair Disorders with Scanning Electron Microscopy: An Update
J Hicks¹; ¹Texas Children's Hospital and Baylor College of Medicine, Houston, Texas

59 Multinodular Goiter Leading to Diagnosis of Minimally Invasive Follicular Thyroid Carcinoma and DICER1 Syndrome in an 18-year-old Female
E Schuele¹, S Besmer²; ¹Saint Louis University School of Medicine, St. Louis; ²Saint Louis University/ Cardinal Glennon Children's Hospital, St. Louis

60 The Spectrum of Sub-Saharan African Pediatric Pathology: A novel, systematic epidemiological assessment at a national referral hospital in Kampala, Uganda
J Kasten¹; ¹Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

61 Evaluating the Anticipated Molecular Alterations for Pediatric CNS Neoplasms Using a Targeted DNA and RNA Sequencing Gene Panel
M Aldulescu¹, N Wadhwani¹; ¹Lurie Children's Hospital, Chicago, Illinois
Sunday, March 1, 2020

8:00 a.m. – 9:30 a.m.
Platform Session 3 – Neuropathology and Immuno-oncology

Moderators: Jiancong Liang, MD & Sanda Alexandrescu, MD

Room: Golden Ballroom

8:00 – 8:15 a.m. 14
Tumor Neoantigens in Synovial Sarcoma for Immunotherapy
M He1, M Kaushal1, C Liu1, B Abro1, L Dehner1, J Pfeifer1; 1Washington University School of Medicine in St. Louis, St. Louis

8:15 – 8:30 a.m. 15
Comparative Histopathologic Features of FGFR Fusion Pediatric and Adult Central Nervous System Tumors
A Gilani1, K Davies2, B Kleinschmidt-DeMasters1; 1Children's Hospital Colorado, University of Colorado, Aurora, Colorado; 2University of Colorado CMOCO, Aurora, Colorado

8:30 – 8:45 a.m. 16
PD-L1 expression in Pediatric Angiomatoid Fibrous Histiocytoma
J Byers1, H Yin2, H Rytting2, S Logan2, M He3, Z Yu3, D Wang2, M Warren1, S Mangray4, L Dehner3, S Zhou1; 1Children’s hospital Los Angeles, Los Angeles; 2Children’s Healthcare of Atlanta, Atlanta, Georgia; 3Washington University in Saint Louis, Saint Louis, Missouri; 4University of Oklahoma Health sciences center, Oklahoma, Oklahoma; 5Cincinnati Children’s Hospital, Cincinnati, Ohio; 6Rhode Island Hospital, Providence, Rhode Island

8:45 – 9:00 a.m. 17
Melanotic Neuroectodermal Tumor Of Infancy (MNTI) Harbors A Medulloblastoma Signature By DNA Methylation Profiling
O Lopez-Nunez1, R Alaggio2, A Ciofli2, A Mastronuzzi2, F Giangaspero2, L Santoro3, V Donofrio4, L Surrey5, E Miele2; 1UPMC Children's Hospital of Pittsburgh, Pittsburgh, USA; 2Ospedale Pediatrico Bambino Gesù (OPBG), Rome, Italy; 3Azienda Ospedaliera di Padova, Padova, Italy; 4Azienda Ospedaliera Santobono-Pausilipon, Naples, Italy; 5Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

9:00 – 9:15 a.m. 18
Prevalence of Hippocampal Abnormalities and a History of Seizures in Sudden Unexpected Death in Childhood and its comparison with Sudden Unexpected Death in Epilepsy and SIDS: A 16-years Single Centre Review
F Kon1, R Zapata Vazquez2, A Lang3, M Cohen3; 1University of Sheffield, Sheffield, England; 2University Autonoma de Yucatan, Merida, Mexico; 3Sheffield Children's Hospital, Sheffield, England

9:15 – 9:30 a.m. 19
PD-L1/PD-1 Expression in Wilms Tumor: Analysis of 52 Cases
J Chen1, J Mattis1, I Gonzalez1, R Rais1, L Dehner1, J Pfeifer1, M He1; 1Washington University School of Medicine, St Louis
9:30 a.m. – 10:30 a.m.  
Platform Session 4 – GI/Pulmonary  
Moderators: Lili Miles, MD & Shengmei Zhou, MD  

9:30 - 9:45am  
Distinct Mucinous Cell Clusters in Type I Congenital Pulmonary Airway Malformations Carry Clonal KRAS Mutations  
N Nelson1, F Xu2, M Li2; J Pogoriler2; 1Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; 2Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

9:45 - 10:00am  
Centrilobular Injury Pattern is Not Indicative of Antibody Mediated Rejection in Pediatric Liver Transplant  
I González1, H Lu1, L Dehner1, M He1; 1Washington University School of Medicine, St. Louis, Missouri

10:00 - 10:15am  
Utility of Phox2B Immunohistochemical Staining in Hirschsprung Disease  
M Alturkustani1, S Zhou1, L Wang1, N Shillingford1, M Warren1; 1Children's Hospital Los Angeles, Los Angeles, California

10:15 - 10:30am  
Robarts and Nancy Histopathologic Indices Highlight the Significance of Pancolonic Biopsies in Pediatric Ulcerative Colitis  
J Putra1, A Ricciuto1, P Church1, T Walters1, A Griffiths1, I Siddiqui1; 1Hospital for Sick Children, Toronto

11:00am – 12:00noon  
Farber-Landing Lecture:  
Rhabdomyosarcoma: From Obscurity to Clarity in Diagnosis, but with Ongoing Challenges in Management  
David Parham, MD

At the end of this presentation, participants should be able to:  
- Describe the concepts and history behind the current standard of rhabdomyosarcoma diagnosis  
- Recognize morphological and biological variants of rhabdomyosarcoma  
- Recite the current therapeutic standards for rhabdomyosarcoma and how they are affected by modern genetic testing

12:00 noon - 12:20 p.m.  
Awards Presentation

Please Note: Entry into workshops will require an admission ticket which will be collected by SPP Staff at the door. Tickets may be available at the SPP registration desk. The Education Committee requests that registrants respect this policy and not attempt to enter without an admission ticket.

1:30 p.m. – 3:30 p.m.  
Workshop Session I:

A. Year 1/3: NEW! Discovering Cancer Predisposition in Children  
John Hicks, MD, Texas Children's Hospital; Kyle Kurek, MD, University of Calgary

At the end of this presentation, participants should be able to:  
1. List unusual presentations, disease processes, lesions and/or neoplasms that are associated with cancer predisposition syndromes in pediatrics  
2. Describe clinical, pathologic and outcome features of cancer predisposition syndromes
3. Describe the various methods necessary to identify the genetic alterations in cancer predisposition syndromes
4. Describe the pathophysiology and role of pathologist in recognition and diagnosis of syndromes
5. Describe challenges associated with molecular diagnosis and the associated challenges: 1) describe genetic variants, somatic vs germline mutations; 2) describe interpretation of variants of unknown significance; and 3) describe patient consent issues in molecular testing

B. Year 2/3: What Can the Placenta Tell Us?  Room: Sacramento
Debra S. Heller, MD, Rutgers-New Jersey Medical School, Rebecca N. Baergen, MD, Weill Cornell Medical College – New York Presbyterian Hospital

At the end of this presentation, participants should be able to:

- Diagnose placental lesions with a risk of recurrence in future pregnancies
- Diagnose placental lesions associated with neurologic injury and stillbirth
- Recite the terminology used in placental pathology including the Amsterdam Placental Workshop Guidelines

C. Year 3/3: What Every Pediatric Pathologist Needs to Know:  Room: Los Angeles
WHO Classification of Tumors of the Central Nervous System Pediatric Tumors – FINAL YEAR!
Alexander Judkins, MD, Children's Hospital Los Angeles; Jennifer Cotter, MD, Children's Hospital Los Angeles; and Mariarita Santi, MD, Children's Hospital of Philadelphia

At the end of this presentation, participants should be able to:

- Apply the 2016 WHO Classification of Tumors of the Central Nervous System to the diagnosis of medulloblastoma
- Integrate morphologic and molecular results into a comprehensive pathology report for the diagnosis of medulloblastoma
- Apply immunohistochemical and molecular techniques to determine medulloblastoma molecular subgroup
- Appreciate the clinical relevance of molecular subgrouping and TP53 mutation status in medulloblastoma
- Apply the 2016 WHO Classification of tumors of the Central Nervous System to the diagnosis of pediatric embryonal CNS tumors (non-medulloblastoma)
- Integrate morphologic and molecular results into a comprehensive pathology report for the diagnosis of pediatric embryonal CNS tumors (non-medulloblastoma)
- Distinguish AT/RT lacking histological features of rhabdoid differentiation from other pediatric CNS embryonal tumors on the basis of immunohistochemistry and/or molecular analysis of SMARCB1/INI1 and/or SMARCA4/BRG1
- Using their molecular profile, distinguish C19MC-altered embryonal tumors from other pediatric embryonal CNS tumors
- Apply the 2016 WHO Classification of tumors of the Central Nervous System to the diagnosis of pediatric glial tumors
- Approach the diagnosis of pediatric glial brain tumors using a combination of morphology and molecular diagnostic techniques
- Distinguish the BRAF mutated glial tumors from the Histone-3 mutated tumors and extrapolate the prognostic implications
- Separate the molecular profile of supratentorial ependymomas from the infratentorial
- Integrate morphologic and molecular results into a comprehensive pathology report
D. Year 1/3: NEW! Hirschsprung Disease: Diagnostic, Intra-Operative, and Post-Operative
Raj P. Kapur, MD, PhD, Seattle Children's Hospital; Miguel Reyes-Mugica, MD, University of Pittsburgh Medical Center

At the end of this presentation, participants should be able to:

• List two H&E, one enzyme histochemical, and two immunohistochemical findings found in the majority of rectal biopsies from patients with Hirschsprung disease and recognize the diagnostic features and limitations of each.
• List three H&E features of transition zone and recognize their diagnostic characteristics.
• Advise a surgeon how to proceed with pull-through resection based on either identification of ganglion cells in a leveling biopsy or features of transition zone in a circumferential section from the proximal resection margin.
• Conduct a comprehensive gross and microscopic examination of a Hirschsprung resection specimen to document clinically relevant anatomic pathology.

E. Year 2/3: Role of Bias in Pediatric Pathology: Preventing Errors and Enhancing Patient Safety One Child at a Time – an American Board of Pathology approved Patient Safety Course!
Vinay Prasad, MD, MPH, Brandon Regional Hospital & Kathleen Nicol, MD, Nationwide Children’s Hospital

At the end of this session, participants should be able to:

• Identify human factors that contribute to errors and patient safety
• Create a culture of safety within their laboratory areas
• Implement methods and tools for avoiding medical errors
• Identify diagnostic errors specific to pediatric pathology and pediatric laboratory medicine
• Describe systems thinking and the effect of the system on patient safety
• Describe epidemiology of error in laboratory medicine
• Recite the fundamentals of quality improvement

F. Year 3/3: Bone Dysplasias: A Systematic Diagnostic Approach – FINAL YEAR!
Linda Ernst, MD, NorthShore University HealthSystem, Evanston Hospital & Peter Nikkels, MD, University Medical Center Utrecht

At the end of this session, participants should be able to:

• Describe the diagnostic histological aspects of some common skeletal dysplasia’s recognizable at birth
• Describe the diagnostic features of the X-rays of several common skeletal dysplasia’s recognizable at birth
• Recognize the limitations of histology to diagnose a skeletal dysplasia
• Use a diagnostic scheme to diagnose the more common skeletal dysplasia’s recognizable at birth